Johny Marice
New research published in the journal Autism Research has fundamentally altered the scientific understanding of Phelan-McDermid syndrome (PMS), suggesting that the condition is significantly more prevalent than earlier clinical estimates indicated. Led by the Seaver Autism Center for Research and Treatment at Mount Sinai, the study concludes that approximately 1 in 7,300 individuals may be living with this rare genetic disorder. This projection suggests that more than 45,000 people in the United States alone could be affected, a figure that highlights a substantial diagnostic gap in the neurodevelopmental landscape.
Defining Phelan-McDermid Syndrome
Phelan-McDermid syndrome is a complex genetic condition primarily caused by a deletion or mutation involving the SHANK3 gene, located on chromosome 22. The SHANK3 protein plays a critical role in the formation and function of synapses, the junctions where nerve cells communicate within the brain. When this gene is compromised, the downstream effects are extensive, often manifesting as a broad spectrum of medical, intellectual, and behavioral challenges.
Clinical presentations of PMS vary widely but frequently include moderate to severe intellectual disability, delayed or absent speech, hypotonia (low muscle tone), and a heightened risk of seizures. Notably, there is a strong clinical intersection between PMS and autism spectrum disorder (ASD); a majority of individuals diagnosed with PMS also meet the diagnostic criteria for autism. Current estimates suggest that mutations or deletions involving the SHANK3 gene may account for as many as one percent of all ASD cases globally.
Chronology of Diagnostic Evolution
The history of PMS research is relatively recent. The condition was first described in the late 1980s and early 1990s, but it remained largely obscure due to the limitations of historical genetic testing technology. For decades, standard clinical procedures—such as karyotyping—were unable to detect the subtle microdeletions on chromosome 22 that characterize the syndrome.
It was not until the widespread adoption of chromosomal microarray analysis (CMA) and, more recently, next-generation sequencing (NGS), that researchers began to appreciate the true breadth of the disorder. Throughout the 2010s, as genetic screening became more affordable and accessible, the number of identified cases rose, but a significant disparity remained between suspected prevalence rates and confirmed clinical diagnoses. The current Mount Sinai study represents the most comprehensive attempt to date to bridge this gap, utilizing massive datasets to move beyond localized clinical observations.
Methodology and Supporting Data
To reach their conclusions, the research team at Mount Sinai conducted a rigorous analysis involving nearly 180,000 individuals with autism who had undergone genetic testing. The methodology relied on the aggregation of data from ten distinct sources, creating a robust, multi-institutional evidence base. Participating entities included GeneDx, Labcorp, Ambry Genetics, the SPARK research study, and the Autism Sequencing Consortium, alongside contributions from major pediatric medical centers.
The researchers applied a sophisticated statistical model to account for several confounding factors:
- Undiagnosed Populations: The team estimated the number of individuals who possess the genetic marker but have not been identified through the current medical system.
- Testing Limitations: The study acknowledged that many standard genetic panels lack the sensitivity to detect specific SHANK3 mutations, leading to false negatives.
- Phenotypic Diversity: Researchers accounted for individuals who have the genetic deletion but fall outside the typical autism diagnostic criteria, meaning they might never be referred for autism-specific genetic testing.
After adjusting for these variables, the team arrived at a prevalence rate of 13.7 cases per 100,000 people, resulting in the 1 in 7,300 ratio. This figure represents a major departure from older, more conservative estimates, which had previously painted the condition as significantly rarer.
Expert Perspectives and Official Responses
The implications of these findings are being felt across the genetic counseling and pediatric neurology communities. Tess Levy, MSc, Assistant Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai and the study’s first author, noted that the “large gap” between known and estimated cases is a systemic issue.
"Many individuals with developmental disabilities and autism are never offered genetic testing," Levy stated. "Families may face insurance barriers or may receive tests that do not adequately evaluate the SHANK3 gene."
Dr. Joseph D. Buxbaum, PhD, Director of the Seaver Autism Center and the study’s senior author, emphasized that the shift in prevalence estimates should change clinical practice. "We recommend that every child with autism undergo genetic testing, because knowledge is power," Buxbaum said. He projected a optimistic timeline for the field, noting, "I truly believe that within the next five years, we’ll see successful examples of new treatments coming from these genetic discoveries."
Industry partners, including CureSHANK and Neuren Pharmaceuticals, played a pivotal role in funding and facilitating this research. Rachel Groth, PhD, Head of External Innovation and Patient Advocacy at Neuren Pharmaceuticals, described the study as an "ethical imperative." She noted that as therapeutic research accelerates, the ability to identify patients becomes a prerequisite for clinical success. "Patients cannot benefit from these advances if they never receive a diagnosis," Groth added.
The Shift Toward Precision Medicine
The publication of this study comes at a transformative moment for PMS treatment. With the underlying biology of the SHANK3 gene better understood, pharmaceutical companies and academic labs are moving away from purely symptomatic management toward precision medicine—treatments designed to target the biological roots of the syndrome.
Several clinical trials are currently in the recruitment or active phase, focusing on novel therapeutics that aim to stabilize synaptic function. For families, the value of a genetic diagnosis has evolved. It is no longer merely a tool for diagnostic closure; it is now a gateway to clinical trials and personalized care pathways.
Geraldine Bliss, Board Chair of CureSHANK, underscored the human element of the research findings. "This study confirms what many families, clinicians, and advocates have suspected for years," Bliss said. "There are likely tens of thousands of individuals with Phelan-McDermid syndrome who have never received a genetic diagnosis. At a time when multiple therapeutics are advancing into clinical trials, finding these individuals has never been more important."
Broader Implications and Future Directions
The results of this study serve as a catalyst for the "Start Genetic" campaign, a global initiative that advocates for a "think genetic first" approach in clinical settings. The goal is to standardize genetic testing for children presenting with developmental delays or autism, moving away from a reactive model toward a proactive, diagnostic-heavy standard of care.
From a public health perspective, the study highlights a critical inefficiency: medical technology has outpaced diagnostic access. While the tools to identify rare conditions like PMS exist, the infrastructure to deliver these tests to the broader population—especially those in underserved communities or those lacking specialized insurance coverage—remains fragmented.
The economic and social implications are equally significant. Early identification of Phelan-McDermid syndrome allows for earlier intervention, better access to specialized educational resources, and, eventually, enrollment in trials for potentially disease-modifying therapies. As the medical community digests these new prevalence figures, the emphasis is expected to shift toward expanding diagnostic reach.
Ultimately, the Mount Sinai study serves as a diagnostic wake-up call. By confirming that PMS is significantly more common than once thought, researchers have provided the necessary data to justify increased clinical focus and funding. The challenge moving forward will be to ensure that these diagnostic advancements translate into tangible, accessible clinical outcomes for the estimated 45,000 people in the United States currently living without a name for their condition. As the landscape of autism research continues to integrate deeper genomic insights, the story of Phelan-McDermid syndrome remains a primary example of how precise, data-driven science can redefine the trajectory of patient care.
